Immunogenicity of yeast-derived hepatitis B vaccine from two different producers

Dahl-Hansen, E.; Siebke, J. C.; Ss, Frøland; Degré, Miklos

doi:10.1017/s0950268800054625

Cited by 20 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As all volunteers recruited in this study belonged to a young age group and were considered healthy, a rela-tively high vaccine response rate was obtained. The seroconversion rates in anti-HAV/HBsAb-negative volunteers to the combined hepatitis A/hepatitis B vaccine were at least equivalent to those obtained with monovalent hepatitis A or hepatitis B vaccines [4][5][6][7][8][9][10]. Subjects in group 2 responded better, both in terms of seroconversion and antibody production, to the HAV compound than subjects in group 1.…”

Section: Discussionmentioning

confidence: 78%

Production of antibody to hepatitis A virus and hepatitis B surface antigen measured after combined hepatitis A/ hepatitis B vaccination in 242 adult volunteers

Reutter

Bart

Francioli

et al. 1998

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Two batches of a new hepatitis A/hepatitis B combined vaccine were tested in 242 healthy students. Three injections, given at 0, 1 and 6 months, produced seroconversion rates and hepatitis A virus (HAV) and hepatitis B surface antigen (HBsAg) antibody levels comparable to those reported after administration of separate monocomponent vaccines. The vaccine proved to be safe and well-tolerated. Influence of host factors, such as elevated body mass index or gender, were investigated and proven to be of little influence on the immunoresponse.

show abstract

Section: Discussionmentioning

confidence: 78%

Production of antibody to hepatitis A virus and hepatitis B surface antigen measured after combined hepatitis A/ hepatitis B vaccination in 242 adult volunteers

Reutter

Bart

Francioli

et al. 1998

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…From published data [Jilg et al, , 1988Heijtink et al, 1985;Papaevangelou et al, 1985;Weber et al, 1985;Stevens et al, 1987;Crovari et al, 1988;Taylor et al, 1988;Marinho et al, 1988;Shaw et al, 1989;West, 1989;Zajac et al, 1989;Dahl-Hansen et al, 1990;Hadler, 1990;Street et al, 1990;Dentico et al, 1991;Renzulli et al, 1992;Oates et al, 1993;Treadwell et al, 1993;Wood et al, 1993;Chiaramonte et al, 1996;Pride et al, 1998;Jones et al, 1999;Heijtink et al, 2000] and national vaccination guidelines [UK Department of Health Advisory Group on Hepatitis, 1993; Morgan, 1995], we anticipated that the protection rate in healthy normal younger adults would be 90 to 95% with the standard three-dose regimen of current single antigen vaccines, and since this study allowed all ages to be recruited with randomisation strati®ed for age group (above or below 40 years) to ensure balance, we anticipated the overall Recombivax-HB protection rate would be at the lower end of the above range.…”

Section: Discussionmentioning

confidence: 99%

Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination*

Young¹,

Gooch²,

Zuckerman³

et al. 2001

Journal of Medical Virology

View full text Add to dashboard Cite

Hepatitis B and its sequelae are a major public health problem. Vaccines have been available for almost 20 years; however the disease still remains a global problem. Many factors contribute to the failure to control hepatitis B, including the limited nature of the vaccination programs implemented initially. Only relatively recently has mass childhood vaccination begun to be implemented and vaccination of high-risk groups, other than healthcare workers, is still not general policy. Additional factors contributing to continued persistence of hepatitis B in the developed world are that the present vaccines are not fully used by those recommended to be vaccinated and even when vaccination is carried out appropriately, there remain some who fail to achieve adequate protection. Clearly, the protection of at-risk groups who have inadequate response to current vaccines, and those who are unwilling or unable to comply with protracted multi-dose vaccine regimens, could be improved if there were a more potent vaccine and/or a shorter vaccination regimen available. Adults who had never been vaccinated against hepatitis B were randomised to receive a vaccination course of either a present single antigen (S) vaccine (Recombivax-HB) or a novel triple antigen (S, pre-S1, and pre-S2) recombinant vaccine (Hepacare Medeva Pharma plc). Doses were given at baseline and 1 month and 6 months later. Hepatitis B surface antibody (anti-HBs) levels were measured at 2, 4, 6, and 7 months after beginning vaccination. The primary efficacy parameter was the degree of protection, measured as the percentage of subjects with anti-HBs titres > or = 10 IU/L, 6 or 7 months (26 +/- 2 weeks) after beginning vaccination. A total of 303 adult subjects entered the study and were vaccinated. Of these, 11 failed to complete the study (4 on Hepacare and 7 on Recombivax-HB); however all but 2 (1 to receive the triple antigen vaccine and 1 to receive Recombivax-HB) were included in the intent-to-treat population for efficacy evaluation. Treatment randomisation was stratified at entry based on age (above and below 40 years old) and gender. The standard three-dose/6-month vaccination regimen of the single antigen vaccine protected 83% of subjects by 7 months after starting vaccination whereas the triple antigen vaccine as a two-dose/1-month regimen protected 88% within 6 months and as a three-dose/6-month regimen protected 97% by 7 months after starting vaccination. Thus the protection rate provided by the shortened (0, 1) regimen of the novel vaccine was "essentially equivalent" (i.e., not statistically inferior) to that provided by the full (0, 1, and 6) regimen of today's vaccine (88% vs. 81%, P < 0.001), and the protection rate provided by a three-dose/6-month (0, 1, and 6) regimen of the new vaccine was significantly superior to that provided by present vaccines (97% vs. 83% P < 0.001). The percentage of subjects protected increases with time after beginning vaccination and at all time points up to and including 6 months was significantly greater with the ...

show abstract

“…A previous meta-analysis in 2002 observed many factors influencing response to hepatitis B vaccine, especially a decrease response to recombinant HBV vaccine at higher ages11, which suggested that earlier vaccination should be prioritized for prevention at the population level. However, in the last decade, numerous emerging reports, which focused on the seroprotection rate of hepatitis B vaccine in adults12131415161718192021222324252627282930313233343536373839404142434445464748, are still inconclusive to immunize what adults are the most appropriate in order to increase the seroprotection rate. Factors influencing immunologic response to hepatitis B vaccine in adults have been inconsistently examined in existing studies.…”

mentioning

confidence: 99%

Factors influencing immunologic response to hepatitis B vaccine in adults

Yang

Tian

Cui

et al. 2016

Sci Rep

139

126

View full text Add to dashboard Cite

Hepatitis B was still a worldwide health problem. This study aimed to conducted a systematic review and meta-analysis to assess a more precise estimation of factors that influence the response to hepatitis B vaccine in adults. Our included studies examined seroprotection rates close to the end of vaccination schedules in healthy adult populations. This meta-analysis including 21053 adults in 37 articles showed that a significantly decreased response to hepatitis B vaccine appeared in adults (age ≥ 40) (RR:1.86, 95% CI:1.55–2.23), male adults (RR:1.40, 95% CI:1.22–1.61), BMI ≥ 25 adults (RR:1.56, 95% CI:1.12–2.17), smoker (RR:1.53, 95% CI:1.21–1.93), and adults with concomitant disease (RR:1.39, 95% CI:1.04–1.86). Meanwhile, we further found a decreased response to hepatitis B vaccine appeared in adults (age ≥ 30) (RR:1.77, 95% CI:1.48–2.10), and adults (age ≥ 60) (RR:1.30, 95% CI:1.01–1.68). However, there were no difference in response to hepatitis B vaccine both in alcoholic (RR:0.90, 95% CI:0.64–1.26) and 0-1-12 vs. 0-1-6 vaccination schedule (RR:1.39, 95% CI:0.41–4.67). Pooling of these studies recommended the sooner the better for adult hepatitis B vaccine strategy. More vaccine doses, supplemental/additional strengthening immunity should be emphasized on the susceptible population of increasing aged, male, BMI ≥ 25, smoking and concomitant disease. The conventional 0-1-6 vaccination schedule could be still worth to be recommended.

show abstract

Immunogenicity of yeast-derived hepatitis B vaccine from two different producers

Cited by 20 publications

References 11 publications

Production of antibody to hepatitis A virus and hepatitis B surface antigen measured after combined hepatitis A/ hepatitis B vaccination in 242 adult volunteers

Production of antibody to hepatitis A virus and hepatitis B surface antigen measured after combined hepatitis A/ hepatitis B vaccination in 242 adult volunteers

Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination*

Factors influencing immunologic response to hepatitis B vaccine in adults

Contact Info

Product

Resources

About